Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Cheryl Pegus is Director at Boston Scientific. OQRO lists 5 transactions filed with the SEC under this name, the latest on Nov 5, 2026, each linked to the official Form 4.
Director
Disclosures on record
5
Companies involved
2
As of the latest filing on , Cheryl Pegus reported holding 24,729 shares of Concentra Group Holdings Parent, Inc. (CON), worth about $1.07M at the last close of $43 (Nov 16, 2026). Holdings are also on file at Boston Scientific (BSX); together they are worth about $1.15M. In the last 12 months, Cheryl Pegus bought $100K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Concentra Group Holdings Parent, Inc. CON | 24,729 | 25K direct | $43 | $1.07M | Nov 3, 2026 |
| Boston Scientific BSX | 1,770 | 1,770 direct | $44 | $77K | May 20, 2026 |
Is this Cheryl Pegus’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
1 buy, median −16.8 pts vs S&P 500, beat it 0 of 1 time.
Average −16.8 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed May 21, 2026 to May 21, 2026, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 0% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 1 purchases disclosed since 2025-11-16 would be worth $767 today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Concentra Group Holdings Parent, Inc.CON
Nov 3, 20263,989disclosed Nov 5
DetailsOfficial recordBoston ScientificBSX
4 disclosures · Mar 2026 – May 2026 · 1 bought
May 20, 2026Bought~$100Kdisclosed May 21
DetailsOfficial recordMay 7, 20263,800disclosed May 11
DetailsOfficial recordMay 7, 20261,281disclosed May 11
DetailsOfficial recordMar 2, 202624disclosed Mar 5
DetailsOfficial recordOn the latest SEC Form 4, dated Nov 3, 2026, Cheryl Pegus reported holding 24,729 shares of Concentra Group Holdings Parent, Inc. (CON). At the last close of $43 on Nov 16, 2026, that is about $1.07M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Cheryl Pegus reported 1 open-market purchase worth $100K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Cheryl Pegus bought shares on the open market in 2017 and 2026 across 3 companies. Sales in 2 of the 10 years since 2017.
In SEC filings since 2017: the latest open-market purchase is from 2026; the latest open-market sale is from 2020.
3 companies: Boston Scientific (BSX, 2026), Phreesia (PHR, 2019–2020), Tactile Systems Technology (TCMD, 2017).
Cheryl Pegus reported 0 open-market purchases and 4 sales here, 2019 to 2020.
Cheryl Pegus reported 1 open-market purchase and 0 sales here, 2026.
Cheryl Pegus reported 1 open-market purchase and 0 sales here, 2017.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Cheryl Pegus bought shares on the open market in 2017 and 2026 across 3 companies. Sales in 2 of the 10 years since 2017.
Cheryl Pegus reported 2 open-market purchases and 4 sales since 2017; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $100K1×1 trade | — |
| 2020 | — | $1.74M2×2 trades |
| 2019 | — | $17.3M2×2 trades |
| 2017 | $28K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.